跳至主要内容
临床试验/CTRI/2018/01/011118
CTRI/2018/01/011118已完成3 期

A single-blinded, randomized clinical study to evaluate and compare the safety and efficacy of a test hair leave-on product (Hair Tonic) with a comparator product for scalp hair growth and density in healthy male and female subjects

ITC Life Sciences Technology Centre0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1Subjects to be 21 to 55 year old and generally in good health
  • 2Female subjects falling under grade 2, 3 and grade 4 of hair loss severity index as per Ludwig Photo numeric scale.
  • 3Male subjects falling under grade 2, 3 and grade 4 of hair loss severity index as per modified Norwood scale.
  • 4Subject having hair density of 100-200 /cm2.
  • 5Subjects with > 15 strands of fallen hair as assessed by comb test
  • 6Subjects willing to participate in the study voluntarily and agreeing to give their consent for their participation in the study in a signed document.
  • 7Subjects agreeing to maintain the same hairstyle, hair length and hair color throughout the study
  • 8Subjects consenting to have a dot tattoo or markings placed in the target area of the scalp during the study
  • 9Subjects Willing to maintain the habits and products during the study
  • 10Subjects consenting to comply with the study requirements for 6 consecutive months
  • 11Subjects willing to refrain from other AGA/Female pattern hair loss treatments during the entire study duration
  • 12Subjects with no clinically significant disease or abnormal laboratory results taken at the screening visit
  • 13Subjects agreeing to abstain from using any hair growth affecting oral or topical medication including over the counter and herbal medications, finasteride or dutasteride during the course of this study
  • 14Subjects who are not on crash dieting

排除标准

  • 1Subjects who have undergone hair growth treatment 3 months before screening into the study under discussion.
  • 2Subjects having scalp conditions such as folliculitis, seborrheoic psoriasis of scalp, seborrheoic dermatitis and lichen planopilaris at the time of screening.
  • 3Subjects with alopecia areata of scalp hair and scarring alopecia due to any cause such as DLE, SLE and Lichen planus.
  • 4Subjects who have undergone hair straightening using hot iron or chemicals within 3 months prior to the screening.
  • 5Subjects who have undergone treatments of cancer chemotherapy within 6 months before starting study or plan to undergo the same during study course.
  • 6Subjects with a history of alcoholism and/ or psychiatric disorder including trichotillomania.
  • 7Subjects who have had hair transplantation treatment.
  • 8Subjects who take pharmaceutical products that may cause hirsutism (ex. phenytoin) and finesteride for androgenic alopecia.
  • 9Subjects with a known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
  • 10Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
  • 11Subjects who are on oral multivitamin tablets containing biotin, zinc, selenium and unwilling to stop the usage 1 month before enrollment into study and throughout the study duration.
  • 12Subjects with hypertension and thyroid as confirmed by history or blood screening.
  • 13Female subjects who have been pregnant in last 1 year or lactating or nursing as established by medical history or planning to become pregnant during the study period.
  • 14Female subjects with the complaint of post pregnancy hair fall.
  • 15Subjects who have undergone hair dyeing in last 1 month or plan to undergo the same during the study period.
  • 16Subjects with a history of acute severe illness in past 3 months as established by the medical history.
  • 17Subjects suffering from any form of chronic illness which may influence the cutaneous state.
  • 18Subjects participating in other similar cosmetic or therapeutic trial.
  • 19Any underlying uncontrolled medical illness including diabetes mellitus, HIV, hepatitis, anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.

研究者

发起方
ITC Life Sciences Technology Centre

相似试验